U.S. Markets open in 34 mins

AzurRx BioPharma, Inc. (AZRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7811+0.0010 (+0.13%)
At close: 4:00PM EST

AzurRx BioPharma, Inc.

1615 South Congress Avenue
Suite 103
Delray Beach, FL 33445
United States
646-699-7855
http://www.azurrx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Mr. James R. Sapirstein R.Ph., M.B.A.CEO, Pres & Non-Independent Director443.61kN/A1961
Dr. James E. PenningtonChief Medical Officer330kN/A1943
Mr. Martin Krusin M.B.A.Sr. VP of Corp. Devel.N/AN/AN/A
Mr. Daniel H. SchneidermanChief Financial OfficerN/AN/A1978
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. The company's therapeutic products are administered to patients as oral non-systemic biologics. Its lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency for cystic fibrosis and chronic pancreatitis patients. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida.

Corporate Governance

AzurRx BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.